[New MR contrast media in liver diagnosis. Initial clinical results with hepatobiliary Eovist (gadolinium-EOB-DTPA) and RES-specific Resovist (SH U 555 A)]

Synthesis of europium-doped VSOP, customized enhancer solution and improved microscopy fluorescence methodology for unambiguous histological detection

Background

Intrinsic iron in biological tissues frequently precludes unambiguous the identification of iron oxide nanoparticles when iron-based detection methods are used. Here we report the full methodology for synthesizing very small iron oxide nanoparticles (VSOP) doped with europium (Eu) in their iron oxide core (Eu-VSOP) and their unambiguous qualitative and quantitative detection by fluorescence.

Methods and results

The resulting Eu-VSOP contained 0.7 to 2.7% Eu relative to iron, which was sufficient for fluorescent detection while not altering other important particle parameters such as size, surface charge, or relaxivity. A customized enhancer solution with high buffer capacity and nearly neutral pH was developed to provide an antenna system that allowed fluorescent detection of Eu-VSOP in cells and histologic tissue slices as well as in solutions even under acidic conditions as frequently obtained from dissolved organic material. This enhancer solution allowed detection of Eu-VSOP using a standard fluorescence spectrophotometer and a fluorescence microscope equipped with a custom filter set with an excitation wavelength (λ_ex) of 338 nm and an emission wavelength (λ_em) of 616 nm.

Conclusion

The fluorescent detection of Eu-doped very small iron oxide nanoparticles (Eu-VSOP) provides a straightforward tool to unambiguously characterize VSOP biodistribution and toxicology at tissue, and cellular levels, providing a sensitive analytical tool to detect Eu-doped IONP in dissolved organ tissue and biological fluids with fluorescence instruments.

Electronic supplementary material

The online version of this article (doi:10.1186/s12951-017-0301-6) contains supplementary material, which is available to authorized users.

Labeling of mesenchymal stem cells for MRI with single-cell sensitivity

Sensitive cell detection by magnetic resonance imaging (MRI) is an important tool for the development of cell therapies. However, clinically approved contrast agents that allow single-cell detection are currently not available. Therefore, we compared very small iron oxide nanoparticles (VSOP) and new multicore carboxymethyl dextran-coated iron oxide nanoparticles (multicore particles, MCP) designed by our department for magnetic particle imaging (MPI) with discontinued Resovist^® regarding their suitability for detection of single mesenchymal stem cells (MSC) by MRI. We achieved an average intracellular nanoparticle (NP) load of >10 pg Fe per cell without the use of transfection agents. NP loading did not lead to significantly different results in proliferation, colony formation, and multilineage in vitro differentiation assays in comparison to controls. MRI allowed single-cell detection using VSOP, MCP, and Resovist^® in conjunction with high-resolution T2*-weighted imaging at 7 T with postprocessing of phase images in agarose cell phantoms and in vivo after delivery of 2,000 NP-labeled MSC into mouse brains via the left carotid artery. With optimized labeling conditions, a detection rate of ~45% was achieved; however, the experiments were limited by nonhomogeneous NP loading of the MSC population. Attempts should be made to achieve better cell separation for homogeneous NP loading and to thus improve NP-uptake-dependent biocompatibility studies and cell detection by MRI and future MPI. Additionally, using a 7 T MR imager equipped with a cryocoil resulted in approximately two times higher detection. In conclusion, we established labeling conditions for new high-relaxivity MCP, VSOP, and Resovist^® for improved MRI of MSC with single-cell sensitivity.

Targeted delivery of doxorubicin into tumor cells via MMP-sensitive PEG hydrogel-coated magnetic iron oxide nanoparticles (MIONPs)

Targeting tumors with nano-scale delivery systems shows promise to improve the therapeutic effects of chemotherapeutic drugs. However, the limited specificity of current nano-scale systems for cancer tissues prevents realization of their full clinical potential. Here, we demonstrate an effective approach to creating as targeted nanocarriers for drug delivery: MIONPs coated with integrin-targeted and matrix-metalloproteinase (MMP)-sensitive PEG hydrogel scaffolds. The functional PEG hydrogel coating has been designed for active loading as well as triggered intra-cellular release of the cancer therapeutic agent doxorubicin (DOX). Our study demonstrated that coated nanocarriers could be taken into cancer cells 11 times more efficiently than uncoated ones. Furthermore, confocal laser scanning microscopy images revealed that these targeted nanocarriers could efficiently deliver and release DOX into the nuclei of HeLa cells within 2h. Coating MIONPs with multifunctional PEG hydrogel could be a promising alternative to existing vehicles for targeted delivery of DOX into tumor tissue.

Clinical significance of the transitional phase at gadoxetate disodium-enhanced hepatic MRI for the diagnosis of hepatocellular carcinoma: preliminary results

OBJECTIVES

To investigate the clinical significance of the "transitional phase" at gadoxetate disodium (Gd-EOB)-enhanced magnetic resonance imaging for diagnosing hepatocellular carcinoma (HCC).

METHODS

We studied 54 patients with 70 histologically diagnosed HCC. Transitional- and hepatobiliary-phase (TP, HBP) images were acquired 3 and 20 minutes after Gd-EOB injection, respectively. Radiologists measured the size of the hepatic tumors on images and surgical specimens and qualitatively evaluated the signal intensity of the hepatic tumors during TP and HBP independently.

RESULTS

In 4 patients with portal tumor embolism who had undergone percutaneous transhepatic portal embolization and who manifested arterioportal (AP) shunts, the low-intensity area was larger during HBP than TP. Of the 70 HCCs, 4 were of high signal intensity during HBP and 2 were of slightly low intensity during TP.

CONCLUSION

Tumor extension seen during TP rather than HBP more accurately reflected histological findings in patients with HCC with portal tumor thrombi, percutaneous transhepatic portal embolization, or AP shunt.

Effect of lapatinib on hepatic parenchymal enhancement on gadoxetate disodium (EOB)-enhanced MRI scans

We present changes seen on hepatobiliary phase (HBP)-gadoxetate disodium (EOB)-enhanced magnetic resonance image of a woman with liver metastases who was treated with lapatinib. After treatment, the HBP images appeared like portal venous phase images. This suggests that lapatinib, an inhibitor of organic anion transporting polypeptide 1B1, one of the substrates of EOB, inhibits EOB uptake by hepatocytes. In patients treated with lapatinib, the ability to diagnose liver tumors on HBP images may be compromised.

Follow-up of known carcinoid liver metastases: is respiratory-gated t(2) fast spin-echo enough?

PURPOSE

To compare the reliability of T(1)-weighted, T(2)-weighted, and different phases of dynamic contrast-enhanced MRI in the detection and reproducible size assessment of known carcinoid hepatic metastases.

MATERIALS AND METHODS

22 patients with known carcinoid hepatic metastases qualified for the study. Three readers reviewed MRI images twice independently at sessions that were >2 weeks apart. The best sequences for metastases conspicuity, number and size, and reproducibility of size were compared subjectively. Linear mixed models were used to compare the number and size of metastases between readers and sequences, with the significance level set at p < 0.05.

RESULTS

The best overall sequence rated was T(2) FSE (fast spin-echo). The average numbers of metastases was equivalent using T(1)-weighted arterial and T(2) FSE but less for T(2) FRFSE (fast-recovery, fast spin-echo) or delayed imaging. 1,067 lesions were detected and 66 were measured twice by three readers. There was no significant difference between the sequences or between the readings in size measurement when the same sequence was used. However, there was a difference among sequences for size of metastases (p < 0.001).

CONCLUSION

T(2) FSE can be used as a basic sequence in detecting and monitoring the size of carcinoid hepatic metastases and may serve as the primary sequence in patients with contrast allergy or at risk for nephrogenic systemic fibrosis.

[Current status of MRI diagnostics with liver-specific contrast agents. Gd-EOB-DTPA and Gd-BOPTA]

The contrast agents Gd-EOB-DTPA and Gd-BOPTA can be administered by bolus injection and are appropriate for use in MRI both as vascularization markers and markers of hepatobiliary excretion. This contribution presents an overview of the specific characteristics of contrast media and the status of clinical development. In comparison to CT and to MRI with unspecific extracellular Gd-chelates, liver-specific contrast agents offer advantages in differentiating unclear liver lesions, increasing the detection rate, and examining the bile duct system.

Contrast agents in abdominal imaging: current and future directions

Magnetic resonance imaging is an established imaging method for the evaluation of the abdomen. Accurate assessment of the liver, spleen, pancreas, bile ducts, vascular structures, and retroperitoneal organs (eg, the kidneys, the collecting system, and the adrenals) are possible on MR imaging. The intravenous administration of MR contrast agents can frequently improve the examination and provide more specific diagnoses. The advent of more specific, "hepatobiliary" contrast agents has further improved the differential diagnostic process, particularly for MR imaging of the liver. The availability of orally administered MR contrast agents has further extended the range of abdominal applications, making MR imaging of the small bowel and the colon established imaging procedures.

Focal liver lesions: evaluation of the efficacy of gadobenate dimeglumine in MR imaging--a multicenter phase III clinical study

PURPOSE

To evaluate gadobenate dimeglumine (Gd-BOPTA) for dynamic and delayed magnetic resonance (MR) imaging of focal liver lesions.

MATERIALS AND METHODS

In 126 of 214 patients, MR imaging was performed before Gd-BOPTA administration, immediately after bolus administration of a 0.05- mmol/kg dose of Gd-BOPTA, and 60-120 minutes after an additional intravenously infused 0.05-mmol/kg dose. In 88 patients, imaging was performed before and 60-120 minutes after a single, intravenously infused 0.1-mmol/kg dose. T1- and T2-weighted spin-echo and T1-weighted gradient-echo images were acquired. On-site and blinded off-site reviewers prospectively evaluated all images. Intraoperative ultrasonography, computed tomography (CT) during arterial portography, and/or CT with iodized oil served as the reference methods in 110 patients.

RESULTS

Significantly more lesions were detected on combined pre- and postcontrast images compared with on precontrast images alone (P <. 01). All reviewers reported a decreased mean size of the smallest detected lesion and improved lesion conspicuity on postcontrast images. All on-site reviewers and two off-site reviewers reported increased overall diagnostic confidence (P <.01). Additional lesion characterization information was provided on up to 109 (59%) of 184 delayed images and for up to 50 (42%) of 118 patients in whom dynamic images were assessed. Gd-BOPTA would have helped change the diagnosis in 99 (47%) of 209 cases and affected patient treatment in 408 (23%) of 209 cases.

CONCLUSION

Gd-BOPTA increases liver lesion conspicuity and detectability and aids in the characterization of lesions.

Liver-specific MR imaging contrast agents

Liver-specific MR imaging contrast agents consist of iron oxide particles or specially designed paramagnetic complexes targeting either the reticulo-endothelial system of the liver or the hepatocytes. These agents enhance the relaxation of water molecules in normal liver tissue and are excluded from abnormal tissue, such as metastases. Relaxation enhancement provides a map of normal liver function, increasing conspicuity of focal abnormalities. Understanding the indications and use of these agents is a central challenge for radiologists practicing liver MR imaging.